Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MSSTF: Pursuant to the terms and conditions of the Arrangement Agreement, all holders of outstanding Common Shares are entitled to receive CA$0.75 in cash for each Common Share held.
FINRA deleted symbol:
https://otce.finra.org/otce/dailyList?viewType=Deletions
https://biotechinvestmentnews.com/?utm_campaign=mndst_nwlg_ml&utm_medium=print&utm_source=mglg_nwslg&utm_content=msstf_pharma_hlth_cr_lf_sc_wstch
they sent me the brochure in snail mail
Mindset_Files_International_Patent_Application_for_its_Novel_Psilocybin_Synthesis_Method
8/3/21
https://www.globenewswire.com/news-release/2021/08/03/2273666/0/en/Mindset-Files-International-Patent-Application-for-its-Novel-Psilocybin-Synthesis-Method.html
MSSTF_is_on_schedule_to_produce_1Kilo_of_Pharma_Grade_Psilocybin_by_CY21Q4
I agree with you. MSSTF should have no problems selling if they can keep their production deadline
Patents are great but a legal nightmare and financial burden to pursue actions against foreign companies. I'd like to see them bring in some revenue and this stock will start lighting up screens.
Am Most Interested in Patents for Production of more effective/safer psychedelic compounds
Others will need to get the pure pharma grade compounds from someone - why not MSSTF?
I am researching this company so far very interesting.
Superior_Efficacy_and_Improved_Safety_in_Head-to-Head_Comparison_to_Psilocybin_for_its_lead_MSP-1014
7/7/21
https://www.globenewswire.com/news-release/2021/07/07/2258857/0/en/Mindset-Pharma-Announces-Additional-Preclinical-Results-Suggesting-Superior-Efficacy-and-Improved-Safety-in-Head-to-Head-Comparison-to-Psilocybin-for-its-First-Lead-Clinical-Candid.html
MSSTF_is_producing_Pharma_Grade_Psilocybin_California_advances_decriminalizing_psychedelic_substances
6/29/21
https://apnews.com/article/california-health-government-and-politics-c3eb439025f5f0b50090c73f22183cd0
Mindset_Announce_Availability_of_First_Preclinical_Psychedelic_Benchmark_Data_from_COPE_Program
6/3/21_MSSTF_picks_psilocybin-based_compound_MSP-1014_as_lead_clinical_candidate
MSSTF is projected to have lab-grade/Pharma-Grade psilocybin compounds available this fall. All these other psilocybin/psychedelic pennies are gonna need compounds from someone. Why not MSSTF?
MSSTF will hopefully start generating revenues later in CY21 - and is 2-3 years AHEAD of other companies - that are still going thru clinical trials where actual revenues are still 2-3 years away.
6/3/21
https://seekingalpha.com/news/3702844-mindset-pharma-picks-psilocybin-based-compound-msp-1014-as-lead-clinical-candidate
6/5/21
4/29/21_Mindset_Pharma_Announces_Positive_Preclinical_Results_of_Its_Proprietary_Next_Generation_DMT_&_5-MeO-DMT_Compounds
https://www.biospace.com/article/mindset-pharma-announces-positive-preclinical-results-of-its-proprietary-next-generation-dmt-and-5-meo-dmt-compounds/
MSSTF_Has_Agreement_To_Produce_Pharma_Grade_Psilocybin_Using_Patented_Process
Other companies in this space will need access to pharma grade psilocybin.
It has to come from somewhere/someone.
Might as well be MSSTF
Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process
https://www.biospace.com/article/mindset-pharma-reaches-agreement-to-manufacture-large-quantity-of-pharmaceutical-grade-psilocybin-using-patent-pending-synthesis-process/
Serious manipulation of share price IMHO
https://ih.advfn.com/stock-market/USOTC/mindset-pharma-qb-MSSTF/trades
"pursuant to which the Lead Underwriter has agreed, on behalf of a syndicate of underwriters (together with the Lead Underwriter, the "Underwriters"), to purchase, on a "bought deal" basis pursuant to the filing of a short form prospectus, an aggregate of 6,670,000 units of the Company (each, a "Unit") at a price of $0.75 per Unit (the "Issue Price") for aggregate gross proceeds to the Company of $5,002,500 (the "Offering"
https://www.mindsetpharma.com/news/mindset-pharma-announces-5-million-bought-deal-financing
"Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform ("Cope")
https://www.mindsetpharma.com/news/mindset-pharma-and-intervivo-solutions-to-jointly-develop-advanced-cooperative-psychedelics-evaluation-platform-cope-cope-expected-to-be-worlds-first-in-vivo-psychedelic-benchmark-data-set
$MSSTF Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development
https://www.mindsetpharma.com/news/mindset-pharma-expands-scientific-team-dr-malik-slassi-appointed-senior-vp-innovation-and-ian-dean-appointed-director-preclinical-development
Reminds me of when I discovered KUSH :)
Hard to believe no one knows about this company.
Followers
|
0
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
24
|
Created
|
04/09/21
|
Type
|
Free
|
Moderators |
217 Queen Street West
Suite 401
Toronto, ONT M5V 0R2
Canada
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |